|
|||||
|
|
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor |
|
| Authors: | Vittorio Gebbia Maria Rosaria Valerio Alberto Firenze Paolo Vigneri |
| Affiliation: | 1. Medical Oncology Unit, La Maddalena Clinic for Cancer , Palermo, Italy;2. Department of Internal Medicine “Promise”, University of Palermo , Palermo, Italy vittorio.gebbia@gmail.com;4. Medical Oncology Unit, Policlinic P. Giaccone, Palermo, University of Palermo , Palermo, Italy;5. Risk Management Unit, Policlinic P. Giaccone, Palermo, University of Palermo , Palermo, Italy;6. Medical Oncology Unit, Policlinic “G. Rodolico”, University of Catania , Catania, Italy |
| Abstract: | ABSTRACT IntroductionThe discovery and the clinical availability of novel cyclin-dependent kinases 4 and 6 inhibitors have profoundly changed the therapeutic scenario of metastatic hormone receptor-positive breast carcinoma. Among these inhibitors, abemaciclib can induce potent and sustained cell cycle arrest and immune system stimulation. |
| Keywords: | Abemaciclib breast cancer metastases hormonal receptors safety |